BDSX Q1 2023: Core Lung Diagnostics Revenue Soars 86%, Margin Expansion Signals Path to Profitability
Biodesics’ core lung diagnostics business delivered record volume and revenue growth, while margin expansion and payer coverage gains signal a structural pivot away from COVID-era volatility. Execution in sales force productivity and reimbursement is fueling durable improvement, even as biopharma services remain lumpy. With COVID testing now exited, all eyes are on scaling lung diagnostics and unlocking the $9.1 million biopharma backlog to drive sustainable growth.
Summary
- Core Lung Diagnostics Outperformance: Lung test volumes and revenue surged, driving margin gains and operational focus.
- Sales Force Leverage: Field productivity and expanded payer coverage underpin durable volume ramp.
- Biopharma Backlog Watch: Delayed clinical trials weigh on services revenue, but contracted backlog offers latent upside.
Business Overview
Biodesics (BDSX) is a precision diagnostics company specializing in blood-based tests for lung cancer risk assessment, treatment guidance, and monitoring. The company operates two primary lung diagnostics platforms: Notify Lung (risk assessment) and IQ Lung (treatment guidance and resistance monitoring), both supported by proprietary proteomic and genomic assays. Revenue is generated from clinical testing for providers and biopharmaceutical service agreements, with the core lung diagnostics segment now comprising the vast majority of total revenue. COVID-19 testing, once a contributor, has been fully discontinued.
Performance Analysis
Biodesics delivered a decisive shift in business mix and profitability profile in Q1 2023, with core lung diagnostics revenue climbing 86% year-over-year and test volumes up 78%. This expansion was driven by increased physician engagement, the return of patients to care settings, and broadening reimbursement for the Notify lung test portfolio. The company’s five core lung diagnostic tests are now all covered by Medicare, with private payer coverage for Notify XL2 gaining traction and Notify CDT expected to follow.
Gross margin rose sharply to 65% from 51% last year, reflecting the higher mix of lung diagnostics and the wind-down of lower-margin COVID testing. Operating expenses grew due to sales force expansion and travel, but management emphasized cost discipline and a focus on revenue-driving investments. Biopharma services revenue fell 55% year-over-year, as clinical trial delays persisted, yet the $9.1 million contracted backlog positions this segment for future recovery. Cash burn was $12.6 million, with $25.3 million in cash on hand.
- Lung Diagnostics Mix Shift: Core lung diagnostics comprised 95% of Q1 revenue, up from 79% a year ago.
- Margin Expansion: Gross margin improvement was driven by scaling lung test volumes and favorable payer mix.
- Biopharma Volatility: Services revenue remains suppressed, but record RFPs and backlog suggest pent-up demand.
The exit from COVID testing and operational focus on lung diagnostics mark a structural inflection for BDSX, with payer coverage, field execution, and biopharma backlog conversion as the key levers for 2023.
Executive Commentary
"We have established an exceptionally strong double-digit growth trajectory driven by our lung-focused sales team. We are expanding reimbursement of our on-market test with multiple coverage decisions from Medicare and private payers that we anticipate will contribute to our 2023 growth."
Scott Hutton, Chief Executive Officer
"Gross margin percentage in the first quarter of 2023 was 65% versus 51% in the prior year quarter. Current gross margin trends reflect the growth in our higher margin core lung diagnostic testing business and receiving Medicare coverage for our Notify CDT test."
Robin Harper-Cowie, Chief Financial Officer
Strategic Positioning
1. Lung Diagnostics Scale and Coverage Expansion
BDSX is leveraging Medicare and private payer wins to drive adoption of its full suite of lung cancer diagnostics. The Notify XL2 and Notify CDT tests, both blood-based proteomic assays, are seeing accelerating volume as payer coverage broadens. The VA fee schedule inclusion for all five core tests further opens up government channels, with sales reps focused on onboarding and education to unlock utilization.
2. Sales Force Productivity and Market Penetration
Sales team expansion and new associate roles are designed to boost productivity and territory development while containing costs. Management highlighted no evidence of sales rep territory saturation, suggesting further room for organic growth. The field force is balancing academic center and community pulmonologist engagement, with a measured approach to new hires to avoid overextension.
3. Biopharma Services Backlog and Recovery Potential
Biopharma services revenue remains lumpy due to clinical trial enrollment delays, but the $9.1 million contracted backlog and record RFP activity indicate substantial latent demand. Management expects improvement in the second half as trial cadence normalizes, with the segment positioned as an upside lever rather than a core driver in 2023.
4. Clinical Data and Differentiation
Ongoing clinical studies (Oracle and Insight) and upcoming data readouts are designed to reinforce the clinical utility and economic value of the Notify and Veristrat platforms. Interim Oracle data showed a 70% reduction in unnecessary interventions, and the Insight study nears its 5,000-patient milestone, supporting payer and provider adoption.
Key Considerations
This quarter marked a structural pivot for BDSX as management executed on core lung diagnostics scale, margin expansion, and payer access, while biopharma services remain a future call option. Investors should focus on the following:
Key Considerations:
- Margin Sustainability: Gross margin improvement is contingent on continued lung diagnostics volume growth and further payer coverage wins.
- Sales Force Leverage: Field expansion and associate roles aim to boost productivity, but territory development remains variable by region.
- Biopharma Backlog Conversion: The $9.1 million in contracted services revenue is a key upside lever if clinical trial cadence normalizes.
- Cash Burn and Capital Discipline: Operating expense growth is being watched closely, with management signaling a path to profitability but not yet providing a timeline.
- Clinical Data Readouts: Upcoming Oracle and Insight study results are critical for payer and provider adoption, with real-world evidence a major differentiator.
Risks
The primary risks for BDSX are execution-dependent: slower-than-expected payer coverage expansion, biopharma services revenue delays, and the need to balance sales force investment with productivity. Cash burn remains a concern if operating leverage does not materialize, and any reversal in lung diagnostics volume growth or reimbursement could pressure the margin and growth narrative. Biopharma segment volatility and macro headwinds in clinical trial enrollment add uncertainty to the services revenue outlook.
Forward Outlook
For Q2 2023, Biodesics guided to:
- Continued strong year-over-year growth in core lung diagnostics test volumes and revenue
- Gross margin improvement as lung diagnostics mix increases and payer coverage expands
For full-year 2023, management maintained guidance:
- Total revenue of $52 million to $55 million, with no COVID-19 revenue contribution
Management highlighted several factors that will shape the year:
- Broader reimbursement of all five on-market lung tests, including new private payer wins
- Modest biopharma services growth, with backlog conversion expected to accelerate in the second half
Takeaways
BDSX’s Q1 marked a decisive shift toward high-margin, high-growth core lung diagnostics, with operational discipline and payer access at the center of its value proposition.
- Volume and Margin Leverage: Lung diagnostics mix shift and payer wins are structurally expanding margins and setting the foundation for future profitability.
- Field Execution: Sales force investments are translating to record test volume growth, but ongoing productivity and cost management will be key to sustaining momentum.
- Biopharma Optionality: Backlog and RFP trends in services offer upside, but realization is tied to external trial cadence and operational execution.
Conclusion
BDSX’s Q1 2023 results underscore a business now centered on scalable lung diagnostics, margin expansion, and payer access, while biopharma services and cash discipline remain key watchpoints. With COVID testing exited and strong clinical data catalysts ahead, the company is positioned for durable growth, but execution and biopharma conversion will determine the pace and sustainability of value creation.
Industry Read-Through
BDSX’s rapid margin expansion and payer coverage gains highlight the structural advantage of blood-based lung diagnostics over legacy modalities, with implications for peers in oncology diagnostics and precision medicine. The company’s disciplined transition away from COVID testing mirrors broader industry trends as diagnostics players recalibrate to core franchises. Biopharma services volatility and clinical trial delays remain a sector-wide headwind, but record RFP activity and backlog suggest pent-up demand for companion diagnostics and real-world evidence partnerships. Investors should watch for similar margin and mix shifts across the diagnostics space as payers and providers increasingly demand cost-effective, actionable testing solutions.